Anti-Tumor Necrosis Factor (TNF) Biosimilars Virtual Clinic
Optimizing the Management of Immune-mediated Inflammatory Diseases (IMIDs)
Immune-mediated inflammatory diseases (lMIDs) are thought to arise in genetically susceptible individuals when exposure to an environmental trigger generates a pro-inflammatory state that is not adequately controlled by regulatory mechanisms. Central to the pathophysiological process is activation of a pro-inflammatory cytokine loop that amplifies and perpetuates the immune response. Over-expression of cytokines such as tumor necrosis factor (TNF) has led to the successful approval of various biological agents that block TNF. These TNF inhibitors have revolutionized the treatment of IMIDs, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), inflammatory bowel disease (IBD), and psoriasis (PsO). While TNF inhibitors may improve clinical signs and symptoms and may lead to low disease activity and remission, they have posed a significant economic burden to healthcare systems, and, subsequently, to the achievement of therapeutic goals. The advent of more cost-efficient anti-TNF biosimilars is providing more affordable and sustainable options for reducing disease burden in patients with unmet medical needs. In this podcast series on IMIDs, provided by Howitreat.MD by SEI Healthcare, three esteemed clinical experts will discuss opportunities in daily clinical practice to optimize treatment of rheumatoid arthritis, Crohn’s disease, and psoriasis.